N3539
尼可地尔
≥98% (HPLC)
别名:
2-(吡啶-3-羰基氨基)乙基硝酸酯, 2-烟酰胺基硝酸乙酯, N-[2-硝氧乙基]-3-吡啶键酰胺, SG-75, 尼可地尔, 烟浪丁
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C8H9N3O4
CAS Number:
分子量:
211.17
EC 号:
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to off-white
溶解性
DMSO: >10 mg/mL
储存温度
room temp
SMILES字符串
[O-][N+](=O)OCCNC(=O)c1cccnc1
InChI
1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
InChI key
LBHIOVVIQHSOQN-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
应用
尼古拉地尔已被用作钾（K +）通道激活剂和电压门控钙通道抑制剂，用于研究其对人类长QT综合征2（LQTS2）诱导的多能干细胞（hiPSCs）衍生的心肌细胞动作电位（action potential）的影响。
生化/生理作用
尼可地尔是一种杂合ATP敏感性K+（KATP）通道开放剂，也是烟酰胺硝酸盐NO供体。
尼可地尔是一种杂合ATP敏感性K+（KATP）通道开放剂，也是烟酰胺硝酸盐NO供体。尼可地尔能够选择性激活含有SUR2B-和SUR2A-的KATP通道。它可以增强内皮NO合酶的表达，并防止缺血性室性心律失常。尼可地尔通过激活钾离子通道并提供一氧化氮激活鸟苷酸环化酶，引起GMP活化，从而导致动脉和静脉血管舒张。尼可地尔对血管钾离子通道具有选择性，但对心肌收缩和传导没有明显作用。
尼可地尔（Nicorandil ）具有心脏保护作用。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 4 Oral - Org. Perox. D
储存分类代码
5.2 - Organic peroxides and self-reacting hazardous materials
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Shigeo Horinaka
Drugs, 71(9), 1105-1119 (2011-06-30)
Nicorandil, a unique dual pharmacological mechanism anti-anginal agent with adenosine triphosphate sensitive potassium (K(ATP)) channel agonist and nitrate-like properties, provides cardiologists with a means of managing angina pectoris patients effectively and provides long-term cardioprotection. The aim of this review is
A Markham et al.
Drugs, 60(4), 955-974 (2000-11-21)
Nicorandil is a drug with both nitrate-like and ATP-sensitive potassium-channel (K+ ATP) activating properties. By virtue of this dual mechanism of action, the drug acts as a balanced coronary and peripheral vasodilator and reduces both preload and afterload. The K+
L Toquero et al.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 8(8), 717-720 (2006-09-15)
Use of Nicorandil in the treatment of ischaemic heart disease has been associated with oral, ileal and more recently anal ulceration. We report a series of six cases of peri-anal ulceration in patients on nicorandil therapy, their response to withdrawal
V M Smith et al.
The British journal of dermatology, 167(5), 1048-1052 (2012-10-09)
Nicorandil has been available in the U.K. since 1994 for the prophylaxis and treatment of angina. Since the first reported case of nicorandil-associated oral ulceration in 1997 complications elsewhere in the gastrointestinal tract have been reported. Our case series highlights
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure.
Amala A Louis et al.
European journal of heart failure, 4(1), 111-116 (2002-01-29)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持